Le Lézard
Classified in: Health, Science and technology
Subject: HEALTH

Ambiq Propels Remote Healthcare Monitoring Sector Growth with New Ultra-Low Power Processors


News Highlights:

AUSTIN, Texas, July 10, 2023 (GLOBE NEWSWIRE) -- Ambiq®, a technology leader in ultra-low power semiconductor products and solutions, introduces the Apollo4 Lite and Apollo4 Blue Lite SoC to its expanding portfolio of SoCs for IoT endpoint devices, especially the remote monitoring products of the healthcare sector. This announcement follows Ambiq's release of its Heart Kittm, an optimized open-source AI model utilizing multi-head neural networks (MH-NNs) to enable a variety of real-time heart-monitoring applications.

The Apollo4 Lite and Blue Lite product line is the latest generation system processor solutions built upon Ambiq's proprietary Subthreshold Power-Optimized Technology (SPOT®) platform, enabling new features while reducing devices' overall system power consumption to extend their battery life. Both SoCs are embedded with an ultra-low power Cortex-M4 core that can operate at up to 192 MHz with turboSPOT, an audio subsystem, GPU, and ample MRAM and SRAM. They are also conveniently pin-compatible with Ambiq's Apollo4 Plus and Blue Plus¹, providing developers with optimum flexibility for innovation.

"Today's patients are more empowered to monitor and advocate for their own health, and healthcare providers require more data analytics to prescribe holistic treatment," said David Priscak, VP of Technical Solutions at Ambiq. "With bold graphics and long battery life, state-of-the-art health tracking is now more affordable and accessible thanks to these new additions to our Apollo4 SoC family."

"The global remote patient market in terms of revenue was estimated to be worth $53.6 billion in 2022 and is poised to reach $175.2 billion by 2027, growing at a CAGR of 26.7% from 2022 to 2027," said Ms. Anu Dhiman ? Lead Healthcare Analyst ? MarketsandMarkets Research Pvt. Ltd. "The predominant factors influencing the growth of the market include the benefits of remote patient monitoring to reduce the burden on medical resources, the monitoring benefits of telehealth and remote patient monitoring services, advancements in telecommunications, as increasing geriatric population, and the growing need to expand healthcare access."

The Apollo4 Lite and the Apollo4 Blue Lite are designed for extended battery life, advanced security, and powerful graphics in small form factors, which are critical for the continued adoption of these devices. Both are now in mass production, targeting digital health products, smartwatches, fitness bands, animal trackers, voice-activated remotes, industrial maintenance, and smart home IoT devices. For more product information, visit www.ambiq.com/apollo4-lite and www.ambiq.com/apollo4-blue-lite.

¹ ? Apollo4 Lite is pin-compatible with Apollo4 Plus (AMAP42KP-KBR); Apollo4 Blue Lite is pin-compatible with Apollo4 Blue Plus (AMA4B2KP-KXR.)

About Ambiq

Ambiq's mission is to develop the lowest-power semiconductor solutions to enable intelligent devices everywhere by developing the lowest-power semiconductor solutions to drive a more energy-efficient, sustainable, and data-driven world. Ambiq has helped leading manufacturers worldwide develop products that last weeks on a single charge (rather than days) while delivering a maximum feature set in compact industrial designs. Ambiq's goal is to take Artificial Intelligence (AI) where it has never gone before in mobile and portable devices, using Ambiq's advanced ultra-low power system on chip (SoC) solutions. Ambiq has shipped more than 200 million units as of March 2023. For more information, visit www.ambiq.com.

Contact

Charlene Wan
VP of Branding, Marketing, and Investor Relations
[email protected]
+1.512.879.2850

Photos accompanying this announcement are available at

https://www.globenewswire.com/NewsRoom/AttachmentNg/620a2f10-acfe-4d54-b9c3-0983c58c06f6

https://www.globenewswire.com/NewsRoom/AttachmentNg/fd179ebf-2f60-4195-8fca-b88c7b7a852c



These press releases may also interest you

at 05:30
Nutex Health Inc. ("Nutex Health" or the "Company") , a physician-led, technology-enabled integrated healthcare delivery system comprised of 21 state-of-the-art micro hospitals in 9 states and primary care-centric, risk-bearing physician networks,...

at 05:05
MiLaboratories, a leader in RNA immune technologies, and Miltenyi Biotec, a global pioneer in biotechnology, are excited to announce a landmark partnership that promises to revolutionize the field of next-generation therapies. This collaboration...

at 05:02
Immunovia AB (publ) today announced that the Annual Report for 2023 has been published.  The annual report can be downloaded in pdf format and is available on Immunovia's website: https://investor.immunovia.com/financial-reports-presentations/. For...

at 04:19
Medivir AB (STO: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need, announced today that an abstract for the combination of fostroxacitabine bralpamide (fostrox) + Lenvima® in...

at 04:15
Asimov, the synthetic biology company advancing the design and manufacture of therapeutics, today announced the expansion of its LV Edge System with the launch of a fully stable cell line development service. There are now two ways for customers to...

at 04:07
Huma Therapeutics ("Huma"), a leader in global digital health innovation, together with Merck KGaA, Darmstadt, Germany, a leading science and technology company, today announced the launch of their innovative bladder cancer treatment companion app in...



News published on and distributed by: